20140620 - Jun 20, 2014
ISSUE 25 – JUNE 20, 2014PDF



Partnership Points to New Path Forward For Drug Approval and Clinical Research

SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.

The trial, also called Lung Cancer Master Protocol or SWOG S1400, uses the patients’ tumor characteristics to select one of five targeted therapies, comparing them with active control in each arm. 

Lung-MAP is funded by a public-private partnership, which combines NCI’s limited funds with those of commercial sponsors, pointing to a new way of pooling resources to conduct faster, more efficient registration trials. 

Conversation with The Cancer Letter
What $34,000 per Patient Buys in Lung-MAP

The Cancer Letter asked David Wholley, director of research partnerships for the Foundation for the National Institutes of Health, to explain the novel scientific and administrative structure of Lung-MAP.

“For the first five drugs that are going into the trial, NCI is putting in about $24 million, and companies are putting in about $55 million. This would cover the costs for all of the drugs to complete testing through phase III,” he said.

photo90-Ton Cyclotron Delivered To University of Maryland, Touching Off D.C.-Area Proton Radiation Competition

BALTIMORE—Constructed in Germany, shipped to the port of Baltimore, and driven through downtown during the night, the 90-ton cyclotron arrived at the University of Maryland’s Proton Treatment Center.

photo340B Drug Discount Program
HRSA Defends Orphan Drug Rule

Cancer survivors face higher medical costs and productivity losses when compared to people without a cancer history, according to a CDC study published June 13. 

photoIn Brief

  • Patricia LoRusso named associate director of innovative medicine at Yale Cancer Center

  • Corrine Augelli-Szafran named director of chemistry at Southern Research Institute

  • Sandeep Reddy named chief medical officer of Caris Life Sciences

  • Hiromitsu Ota receives award from Wistar Institute

  • Yeshiva University and Montefiore Health System agree on new management structure for Albert Einstein College of Medicine

  • Dana-Farber Cancer Institute and Trovagene Inc. begin collaboration

  • Eli Lilly and Qiagen announce plan to co-develop assay panels

  • Bayer Pharma AG and arGEN-X collaborate to develop therapeutic antibodies

20140613 - Jun 13, 2014
ISSUE 24 – JUNE 13, 2014PDF



Judge’s Order Likely to Derail Federal Rule Clarifying 340B Drug Discount Program

Many people love the 340B Drug Pricing Program. 

Hospitals, clinics and cancer centers rely on it to buy drugs at discounts as deep as 50 percent—and then collect reimbursements that don’t reflect the discount. 

Many others hate 340B, arguing that the federal program gives qualified providers an unfair advantage, and making it even more difficult for office-based oncology practices to survive. 

Guest Editorial
OHSU’s Brian Druker on Accelerating the Pace of Scientific Progress

We are facing a disturbing paradox in science. We have unprecedented potential for advancements spurred by current technologies. But at the same time we are confronting flat to declining funding. 

This climate provides a unique opportunity to examine and improve how we fund research. 

photoGroups Organize Capitol Hill Push for Lung Cancer Screening

The Centers for Medicare and Medicaid Services have another six months to decide whether to cover low-dose computed tomography screening. Yet, proponents of screening seem unwilling to take the chance that Medicare coverage would be restrictive.

To tilt the scale in their favor, they have launched two congressional sign-on letters to CMS.

photoCancer Survivors Face Greater Economic Burdens, Study Says

Cancer survivors face higher medical costs and productivity losses when compared to people without a cancer history, according to a CDC study published June 13. 

photoAs Cigars Gain Popularity Among High School Boys, Legacy Urges FDA Regulation

The number of high school boys who smoke cigars—16.5 percent—is now on par with cigarette use, said the Centers for Disease Control and Prevention.

photoIn Brief

  • Kraft named director of University of Arizona Cancer Center

  • St. Jude redesignated as an NCI Comprehensive Cancer Center

  • AstraZeneca CAMCAR, S.A. partners with Cancer Genetics Inc.

  • Memorial Sloan Kettering forms collaboration with Quest Diagnostics

  • Merck signs agreement with Sysmex Inostics GmbH

  • ASCO publishes suvivorship compendium

  • International health organizations publish guidelines for establishing cancer registries

  • Association of Clinical Research Professionals coordinator designation recognized by ANCC Magnet program

  • The Cancer Letter receives the 2014 Dateline Award for Excellence from the Society of Professional Journalists

20140530 - May 30, 2014
ISSUE 22 – MAY 30, 2014PDF


DePinho Explains Tenure Decision,
Professors Dispute Key Details

Confronted with the prospect of censure by an academic freedom group, Ronald DePinho, president of MD Anderson Cancer Center, is defending his decision to deny tenure renewal to two faculty members.

Responding to an inquiry by the American Association of University Professors, DePinho said that his critics are incorrect in asserting that his administration gave no formal explanation for denying tenure renewal to two faculty members.

photoDePinho’s Letter to the AAUP

Responding to an inquiry by the American Association of University Professors, MD Anderson Cancer Center President Ronald DePinho said his critics are incorrect in asserting that his administration gave no formal explanation for denying tenure renewal to two faculty members.

photoBoyd’s Rebuttal

Douglas Boyd, a professor at MD Anderson, sent his own letter to the American Association of University Professors, responding to DePinho’s version of events.

Boyd is chair of MD Anderson’s Faculty Senate Promotion & Tenure Issues Committee.

photoMoffitt, Ohio State Form Network,
Invite Major Cancer Centers to Join

Moffitt Cancer Center and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this week announced that they are constructing a bioinformatics framework that would enable a multi-center collaboration.

photo
ASCO 2014 Annual Meeting: The Special Awards

 

photoFunding Opportunity
DoD Offering $10.5 Million for Lung Cancer Research

The Department of Defense Lung Cancer Research Program will provide $10.5 million to support innovative, high-impact lung cancer research during fiscal 2014.

photoIn Brief

  • Big Ten Cancer Research Consortium names Susan Goodin exec. officer

  • ASCO launches online resource center for the Affordable Care Act

  • James Graham Brown Cancer Center receives $5.5 million grant

  • MD Anderson signs consulting agreement with Concord Medical Services Holdings for hospital projects in Beijing and Shanghai

  • Mayo Clinic signs agreement with N-of-One for molecular diagnostics

  • CDC is recruiting for director of the Division of Cancer Prevention

photoDrug Approvals

  • FDA approves Vectibix in mCRC with KRAS companion diagnostic

  • European CHMP issues positive opinions for Arzerra in CLL and Halaven in metastatic breast cancer